XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Positive FIND-CKD Results For Kerendia
Why the FIND-CKD result matters for Bayer stock
Bayer (XTRA:BAYN) has drawn fresh attention after its Phase III FIND-CKD study for Kerendia in non-diabetic chronic kidney disease met its primary endpoint, potentially widening the drug’s addressable patient pool.
See our latest analysis for Bayer.
The FIND-CKD news has arrived against a mixed backdrop for Bayer, with a 30 day share price return of 12.12% decline but a 1 year total shareholder return of 72.11% and a weaker 3 year total...